Skip to main content

Table 2 Immunohistochemical positivity of PRMT1, ZEB1, RUNX1 and TWIST1 among different tumor types

From: PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance

Histological subtype PRMT1 ZEB1 RUNX1 TWIST1
+ + + +
ccRCC 73/120 (60.8) 47/120 (39.2) 37/113 (32.7) 76/113 (67.3) 70/117 (59.8) 47/117 (40.2) 112/115 (97.4) 3/115 (2.6)
pRCC I 4/7 (57.1) 3/7 (42.9) 0/7 (0) 7/7 (100) 2/7 (28.6) 5/7 (71.4) 7/7 (100) 0/7 (0.0)
pRCC II 12/16 (75.0) 4/16 (25.0) 1/16 (6.6) 14/15 (93.4) 7/16 (43.8) 9/16 (56.3) 16/16 (100) 0/16 (0.0)
chRCC 12/28 (42.8) 16/28 (57.2) 2/27 (7.1) 25/27 (92.9) 13/28 (46.4) 15/28 (53.6) 28/28 (100) 0/28 (0.0)
RO 24/25 (96.1) 1/25 (9.4) 24/25 (96.0) 1/25 (4.0) 9/25 (36.0) 16/25 (64.0) 25/25 (100) 0/25 (0.0)
CDC 5/7 (71.4) 2/7 (28.6) 3/7 (42.9) 4/7 (57.1) 3/7 (42.9) 4/7 (57.1) 7/7 (100) 0/7 (0.0)
MLCRN-LMP 5/5 (100) 0/0 (0.0) 0/5 (0) 5/5 (100) 5/5 (100) 0/5 (0.0) 5/5 (100) 0/5 (0.0)
P value 0.044* <0.001* 0.149 0.897
  1. Abbreviations: PRMT1, protein arginine methyltransferase 1; ZEB1, Zinc Finger E-Box Binding Homeobox 1; RUNX1, Runt-related transcription factor 1; TWIST1, Twist Family BHLH Transcription Factor 1; ccRCC, clear cell renal cell carcinomas; pRCC I, papillary renal cell carcinoma type I; pRCC II, papillary renal cell carcinoma type I; chRCC, chromophobe renal cell carcinoma;CDC, collecting duct carcinomas-Bellini; MLCRN-LMP, multilocular cystic renal neoplasm of low malignant potential; +, positive; −, negative
  2. *Statistically significant p-value